NCT03452202 Using tDCS in Speech-based Stroke Rehabilitation
| NCT ID | NCT03452202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Apraxia of Speech |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2019-01-11 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2019-01-11 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.
Eligibility Criteria
Inclusion Criteria: * Right-handed * Monolingual (English) * Single left-hemisphere CVA * A minimum of six months post-stroke * Clinical diagnosis of apraxia of speech * Normal speech perception * Passing score on the hearing screening. Exclusion Criteria: * Diagnosis of laryngeal voice disorder * Dysarthria * History of speech impairment prior to CVA * Presence of potential tDCS risk factors: damaged skin at site of stimulation; * Presence of electrically or magnetically activated implant (including pacemaker); * metal in any part of their body; * history of medication-resistant epilepsy in the family; * past history of seizures or unexplained spells of loss of consciousness.
Contact & Investigator
Buchwald Lab
✉ buchwald-lab@nyu.eduAdam Buchwald, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT03452202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Apraxia of Speech. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03452202 currently recruiting?
Yes, NCT03452202 is actively recruiting participants. Contact the research team at buchwald-lab@nyu.edu for enrollment information.
Where is the NCT03452202 trial being conducted?
This trial is being conducted at New York, United States, White Plains, United States.
Who is sponsoring the NCT03452202 clinical trial?
NCT03452202 is sponsored by NYU Langone Health. The principal investigator is Adam Buchwald, MD at NYU Langone Health. The trial plans to enroll 24 participants.